Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania
University of Basel, Basel, Switzerland.
BMJ Glob Health. 2020 Sep;5(9). doi: 10.1136/bmjgh-2020-002681.
Economic analysis of supply chain management interventions to improve the availability of healthcare commodities at healthcare facilities is important in generating evidence for decision-makers. The current study assesses the cost and cost drivers for setting-up a public-private partnership programme in Tanzania in which all public healthcare facility orders for complementary medicines are pooled at the district level, and then purchased from one contracted supplier, the prime vendor (referred to as 'Jazia Prime Vendor System' (Jazia PVS)).
Financial and economic costs of Jazia PVS were collected retrospectively and using the ingredients approach. The financial costs were spread over the implementation period of January 2014-July 2019. In addition, we estimated the financial rollout costs of Jazia PVS to the other 23 regions in the country over 2 years (2018-2019). A multivariate sensitivity analysis was conducted on the estimates.
Jazia PVS start-up and recurrent financial costs amounted to US$2 170 989.74 and US$709 302.32, respectively. The main cost drivers were costs for short-term experts, training of staff and healthcare workers and the Jazia PVS technical and board management activities. The start-up financial cost per facility was US$2819.47 and cost per capita was US$0.37.
In conclusion, the study provides useful information on the cost and cost drivers for setting-up a complementary pharmaceutical supply system to complement an existing system in low-income settings. Despite the substantial costs incurred in the initial investment and operations of the Jazia PVS, the new framework is effective in achieving the desired purpose of improving availability of healthcare commodities.
对供应链管理干预措施进行经济分析,以提高医疗机构医疗商品的可获得性,这对于为决策者提供证据非常重要。本研究评估了在坦桑尼亚建立公私伙伴关系计划的成本和成本驱动因素,该计划将所有公立医院对补充药物的订单在地区一级集中,并从一个合同供应商(主要供应商,简称“Jazia 主要供应商系统”(Jazia PVS))购买。
使用成分法回顾性和前瞻性收集 Jazia PVS 的财务和经济成本。财务成本在 2014 年 1 月至 2019 年 7 月实施期间进行分配。此外,我们还估计了在 2018-2019 年期间将 Jazia PVS 推广到该国其他 23 个地区的财务费用。对估计数进行了多变量敏感性分析。
Jazia PVS 的启动和经常性财务成本分别为 2170989.74 美元和 709302.32 美元。主要成本驱动因素是短期专家、员工和医疗保健工作者培训以及 Jazia PVS 技术和董事会管理活动的成本。每个机构的启动财务成本为 2819.47 美元,人均成本为 0.37 美元。
总之,本研究提供了有关在低收入环境中建立补充药物供应系统以补充现有系统的成本和成本驱动因素的有用信息。尽管 Jazia PVS 的初始投资和运营成本很高,但新框架在实现提高医疗商品供应的预期目标方面是有效的。